For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Tafamidis and the formulated version represents a true advancement . These innovative therapies stabilize the transthyretin protein, preventing its damaging build-up and lessening the burden of the condition . Individuals are now se